Non-invasive cancer treatment with Dr. Antonella Carpenter at Lase Med Inc.
LASE MED, INC. is a Research and Development Nevada Corporation, holding the patent for an improved form of PDT (Photo Dynamic Therapy). The innovation centers in the ability to enhance the absorption of LASER light , of appropriate frequency, by pre-conditioned tumors. The result is the generation of elevated temperature, called hyperthermia, within the tumor and or malignant lesion only, producing inactivation and consequent death of the neoplasm.
This special version of Photo Dynamic Therapy (also called "Photodynamic Therapy") is called L.I.E.S.H. Therapy, and can treat all kinds of skin cancer, including basal cell carcinoma and squamous cell carcinoma, but also melanoma, all types of breast cancer, including infiltrating ductal carcinoma. This LASER cancer treatment can also be used for some cases of lymphoma, Ewing tumors, fibrous sarcoma, Kaposi’s sarcoma and a few other types of cancer.
Although it is a natural version of Photo Dynamic Therapy, this treatment is viewed as an alternative cancer treatment. This is however an improved form of PDT that uses NO DRUGS, using cool laser technology.
Non-invasive cancer treatments can kill cancer in its tracks. Cutting
edge laser cancer treatment, breast cancer and
skin, testicular, topical and Squamous cell carcinoma treatment with Dr. Antonella
Carpenter at Lase Med Inc. We provide non invasive alternative cancer
treatment to treat Melanoma and Basal Cell Carcinoma, stop and kill
Many who have come to Lase Med Inc. have done so only after learning the truth about the "big name" cancer treatment centers the hard way; many have told Dr. Carpenter their personal stories of the horrors experienced at Cancer Treatment Centers of America, Camelot Cancer Care Center, MD Anderson Cancer Center, Oasis of Hope Cancer Hospital, Burzynski Clinic, and Valley Cancer Institute. We look forward to the day when LIESH Therapy and PDT in general will no longer be a "last resort" but a first course of action.